Diabetic atrial fibrillation patients: Mortality and risk for stroke or embolism during a 10-year follow-up

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 4, 2003, Pages 320-328

  Klem, Igor ^a   Wehinger, Cornelius ^a   Schneider, Barbara ^b   Hartl, Elisabeth ^a   Finsterer, Josef ^a   Stöllberger, Claudia ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atrial fibrillation; Diabetes; Heart failure; Hypertension; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BRAIN EMBOLISM; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AUSTRIA; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DIABETIC ANGIOPATHIES; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL EMBOLISM; MALE; MIDDLE AGED; PATIENT SELECTION; REFERENCE VALUES; RISK FACTORS; TIME FACTORS;

EID: 0041592434     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.386     Document Type: Article

References (42)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham study. Stroke 1991; 22: 983-988.
2. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-1457.
3. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFSAK study. Lancet 1989; 1(8631): 175-179.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke inpatients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CAFA Study Investigators. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355.
6. Ezekowitz MD, Bridgers SL, James KE, et al., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
7. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
8. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
9. Hylek EM, Skates SJ, Sheehan MA, Singer De. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
10. Anderson DC, Halperin JL, Hart RG, et al. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke prevention in atrial fibrillation III study. JAMA 1998; 279: 1273-1277.
11. Stöllberger C, Chnupa P, Kronik G, et al., for the ELAT Study Group. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998; 128: 630-638.
12. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. On behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999; 30: 1223-1229.
13. Hart RG, Halperin JL. Atrial fibrillation and stroke. Concepts and controversies. Stroke 2001; 32: 803-810.
14. Stöllberger C, Chnupa P, Abzieher C, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the ELAT (Embolism in left Atrial Thrombi) study. Clin Cardiol 2003; in press.
15. ELAT Study Group. ELAT study (Embolism in left atrial thrombi): baseline clinical and echocardiographic data. Cardiology 1995; 86: 457-463.
16. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
17. Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implication for the development of thrombus. Circulation 1991; 84: 223-231.
18. Kronik G, Stöllberger C, Schuh M, Abzieher F, Slany J, Schneider B. Interobserver variability in the detection of spontaneous echo contrast, left atrial thrombi, and left atrial appendage thrombi by transesophageal echocardiography. Br Heart J 1995; 74: 80-83.
19. Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol 1985; 6: 744-749.
20. Brainin M, Seiser A, Czvitkovits B, Pauly E. Stroke subtype is an age-independent predictor of first-year survival. Neuroepidemiology 1992; 11: 190-195.
21. Mügge A, Daniel WG, Hausmann D, Gödke J, Wagenbreth I, Lichtlen PR. Diagnosis of left atrial appendage thrombi by transesophageal echocardiography: clinical implications and follow-up. Am J Card Imaging 1990; 4: 173-179.
22. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1989; 95(Suppl. 2): 118S-127S.
23. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990; 322: 863-868.
24. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population based estimates. Am J Cardiol 1998; 82: 2N-9N.
25. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
26. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. For the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.
27. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995; 98: 476-484.
28. Önundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardarson Th. Chronic atrial fibrillation - epidemiologic features and 14 year follow-up: a case control study. Eur Heart J 1987; 8: 521-527.
29. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 2001; 250: 382-389.
30. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994; 25: 1127-1164.
31. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-68.
32. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Diabetes Study Group, United Kingdom Prospective Diabetes Study (KPDS) 29. Risk factors for stroke in type 2 Diabetes mellitus. Arch Intern Med 1999; 159: 1097-1103.
33. Toyry JP, Niskanen LK, Lansimies EA, Partanen KPL, Uusitupa MIJ. Anatomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1996; 27: 1316-1318.
34. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2033-2039.
35. Lai SM, Alter M, Friday G, Sobel E. Prognosis for survival after an initial stroke. Stroke 1995; 26: 2011-2015.
36. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995; 38: 1061-1068.
37. Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am 2001; 30: 1011-1030.
38. Wang TD, Chen WJ, Su SS, et al. Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J Cardiovasc Electrophysiol 2001; 12: 877-884.
39. Ihlemann N, Stokholm KH, Eskildsen PC. Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated type 2 diabetes. Diabet Med 2002; 19: 476-481.
40. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51: 1514-1521.
41. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca (+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-1171.
42. Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32: 2246-2252.